← Oncology Approval Tracker

FDA DECISION ·

Augtyro

repotrectinib · Bristol Myers Squibb

Accelerated approvalNew or expanded indicationTumor-agnostic solid tumors
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Adults and children aged 12 years and older with NTRK fusion-positive solid tumors that are locally advanced, metastatic or would require highly morbid surgery, after progression on treatment or when no satisfactory alternative exists.

LAMPGEN ANALYSIS

Why it matters

Repotrectinib gained a tumor-agnostic NTRK indication after its earlier ROS1 lung cancer approval.

What research teams should watch

Distinguish a qualifying fusion from an isolated NTRK variant and document prior TRK-directed therapy and tumor assessment.

PRIMARY RECORDS

Sources